Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Phase I, Single Group Assignment Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TTP607 Administered in Cycles of Five Daily One to Four Hour Infusions to Patients With Advanced Refractory Solid Malignancies.

Next Previous
Trial Profile

An Open Label, Phase I, Single Group Assignment Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TTP607 Administered in Cycles of Five Daily One to Four Hour Infusions to Patients With Advanced Refractory Solid Malignancies.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 27 Oct 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TTP 607 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions

Most Recent Events

  • 27 Jul 2010 Planned end date changed from 1 Jul 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
  • 27 Jul 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
  • 08 Jan 2010 Planned initiation date changed from 1 Jul 2009 to 1 Mar 2010 as reported by ClinicalTrials.gov

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top